Vodobatinib Dosing for CML With Mutation and Tolerability Constraints
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tyrosine kinase inhibitors (TKIs) for treating chronic myeloid leukemia (CML) face challenges such as patient intolerance, adverse events, and development of resistance due to BCR-ABL1 kinase domain mutations, necessitating improved treatment strategies.
Innovation Solution
A novel BCR-ABL1 tyrosine kinase inhibitor (TKI) of Formula I is administered orally with dose escalation or de-escalation to achieve hematologic responses without severe adverse reactions, targeting adult patients with CML in various phases, including chronic, accelerated, and blast phases, and Ph+ ALL, with specific dose ranges and pharmacokinetic parameters to optimize efficacy and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current tyrosine kinase inhibitors (TKIs) are used to treat CML, then hematologic response is achieved, but patient intolerance and severe adverse events occur
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of TKI compounds (Formula I with specific R1-R6 substituents) to alter pharmacokinetic and pharmacodynamic properties. This structural modification achieves improved therapeutic index by maintaining anti-leukemic efficacy while reducing adverse events through optimized molecular parameters
2Reliability
If TKI dosage is increased to improve hematologic response, then disease control improves, but severe adverse reactions increase
Solution Approach 1:
The patent employs parameter changes by establishing optimized dosage ranges (10-210 mg daily) and pharmacokinetic parameters (AUC0-24: 6226-60373 ng*h/mL, Cmax: 664-5054 ng/mL) that achieve effective disease control while avoiding toxicity. The specific compound structure enables this dosage optimization through improved therapeutic window
Solution Approach 2:
The patent applies dynamics through flexible dose escalation and de-escalation strategies that adapt treatment intensity to individual patient response and tolerance. This dynamic dosing approach allows optimization of therapeutic effect while minimizing adverse reactions based on real-time patient status
3Duration of action of stationary object
If TKI treatment is continued long-term to maintain disease response, then sustained hematologic response is achieved, but treatment-emergent adverse events and secondary malignancies develop
Solution Approach 1:
The patent applies parameter changes by modifying TKI chemical structure (Formula I) to achieve improved long-term safety profile. The specific molecular parameters and pharmacokinetic characteristics enable sustained efficacy with reduced cumulative toxicity and lower risk of secondary malignancies compared to prior TKIs
4Reliability
If BCR-ABL1 kinase domain mutations occur during TKI treatment, then TKI binding is impaired, but disease progression continues
Solution Approach 1:
The patent applies parameter changes by designing compound Formula I with specific substituent patterns (R1-R6) that enhance binding affinity and resistance to common BCR-ABL1 mutations. The molecular parameter optimization maintains effective TKI binding even in presence of kinase domain mutations, preventing disease progression
Data Source
AI summary
The present invention relates to methods of treating leukemia using Tyrosine Kinase inhibitors. The invention particularly relates to methods of treating CML and ALL using a compound of Formula I or a pharmaceutically acceptable salt thereof. The compound of Formula 1 has been shown to be efficacious safe and tolerable at a dose from 10 mg to 210 mg.